Clinical Trials Logo

Clinical Trial Summary

Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery with an estimated incidence around 35%. It has been found to be an independent predictor of 30-day and 6-month mortality, stroke, renal failure, respiratory failure, and need for permanent pacemaker among others. Previous studies including meta-analyses demonstrate a protective benefit of prophylactic amiodarone to decrease the risk of POAF. However, this has not been widely adopted, and recent society guidelines only give prophylactic amiodarone a Class IIA recommendation, citing risk of amiodarone-related toxicity and hypotension as reasons for the Class IIA recommendation. A meta-analysis comparing cumulative doses of amiodarone found that moderate to higher doses of amiodarone have a marginally increased benefit in reducing the incidence of postoperative atrial fibrillation over lower doses; however, the study did not assess risk of complications stratified by cumulative doses, which has been previously described. Finally, a recent meta-analysis showed that a posterior pericardiotomy was highly effective at reducing postoperative atrial fibrillation. Consequently, the investigators' institution has adopted a pharmaco-surgical approach (prophylactic amiodarone and posterior pericardiotomy) in an effort to reduce postoperative atrial fibrillation after coronary artery bypass cardiac surgery for all patients who meet inclusion/exclusion criteria.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05780320
Study type Observational
Source Massachusetts General Hospital
Contact
Status Active, not recruiting
Phase
Start date September 19, 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Recruiting NCT04870424 - Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Phase 3
Completed NCT05818592 - Screening for Atrial Fibrillation With Self Pulse Monitoring N/A
Active, not recruiting NCT03866148 - Obstructive Sleep Apnoea and Cardiac Arrhythmias N/A
Withdrawn NCT05656170 - Stellate Ganglion to Prevent Atrial Fibrillation N/A
Active, not recruiting NCT05255224 - PARADISE: Predicting AF After Cardiac Surgery
Recruiting NCT04528511 - BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Recruiting NCT04857268 - Diagnostic Validation of Wearable ECG Monitoring Patch, ATP-C120 N/A
Completed NCT04118270 - Shared Decision-Making: AFib 2gether Mobile App N/A
Active, not recruiting NCT03345615 - Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation N/A
Not yet recruiting NCT05841056 - Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial Phase 3
Recruiting NCT05149820 - Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments Phase 4
Completed NCT03221777 - Atrial Fibrillation Occurring Transiently With Stress (AFOTS)
Not yet recruiting NCT03991754 - Prevention of New Onset AF After TAVI (PAF-TAVI Trial) Phase 3
Completed NCT03118518 - STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation N/A
Completed NCT03552588 - High Sensitivity Estimate of the Incidence of Atrial Fibrillation Occurring Transiently With Stress (AFOTS Incidence Study)
Recruiting NCT05444335 - Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years N/A
Terminated NCT05950971 - Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation N/A
Recruiting NCT05287191 - MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care Phase 3
Recruiting NCT05300555 - Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery Phase 4